Both the classical and alternative non-homologous end joining pathways contribute to the fusion of drastically shortened telomeres induced by TRF2 overexpression.

The double-stranded telomeric binding protein TRF2 is expressed in many human cancers at elevated levels. Moreover, experimental overexpression of TRF2 in human cells causes replication stalling in telomeric tracts, which leads to drastic telomere shortening and fusion of deprotected chromosome ends. To understand which end joining pathway is involved in mediating these chromosome fusions, we overexpressed TRF2 in human HCT116 cell lines that were deficient for the DNA Ligase 4 (Lig4)-dependent classical non-homologous end joining (C-NHEJ) or the DNA Ligase 3 (Lig3)-dependent alternative non-homologous end joining (A-NHEJ) pathway.

Elevated levels of TRF2 induce telomeric ultrafine anaphase bridges and rapid telomere deletions.

The shelterin protein TRF2 is essential for chromosome-end protection. Depletion of TRF2 causes chromosome end-to-end fusions, initiating genomic instability that can be cancer promoting. Paradoxically, significant increased levels of TRF2 are observed in a subset of human cancers.

Real-time detection of β1 integrin expression on MG-63 cells using electrochemical impedance spectroscopy.

Beta 1 integrin is a membrane protein responsible for attachment and migration of osteosarcoma cells. In this study, expression of β1 integrin on MG-63 cells, a human osteogenic sarcoma cell line, was monitored using electrochemical impedance spectroscopy (EIS). ITO-based biochips were developed using a semiconductor technique.